HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signaling.

Abstract
Despite encouraging preclinical data, therapies to reduce ARDS mortality remains a globally unmet need, including during the COVID-19 pandemic. We previously identified extracellular nicotinamide phosphoribosyltransferase (eNAMPT) as a novel damage-associated molecular pattern protein (DAMP) via TLR4 ligation which regulates inflammatory cascade activation. eNAMPT is tightly linked to human ARDS by biomarker and genotyping studies in ARDS subjects. We now hypothesize that an eNAMPT-neutralizing mAb will significantly reduce the severity of ARDS lung inflammatory lung injury in diverse preclinical rat and porcine models. Sprague Dawley rats received eNAMPT mAb intravenously following exposure to intratracheal lipopolysaccharide (LPS) or to a traumatic blast (125 kPa) but prior to initiation of ventilator-induced lung injury (VILI) (4 h). Yucatan minipigs received intravenous eNAMPT mAb 2 h after initiation of septic shock and VILI (12 h). Each rat/porcine ARDS/VILI model was strongly associated with evidence of severe inflammatory lung injury with NFkB pathway activation and marked dysregulation of the Akt/mTORC2 signaling pathway. eNAMPT neutralization dramatically reduced inflammatory indices and the severity of lung injury in each rat/porcine ARDS/VILI model (~ 50% reduction) including reduction in serum lactate, and plasma levels of eNAMPT, IL-6, TNFα and Ang-2. The eNAMPT mAb further rectified NFkB pathway activation and preserved the Akt/mTORC2 signaling pathway. These results strongly support targeting the eNAMPT/TLR4 inflammatory pathway as a potential ARDS strategy to reduce inflammatory lung injury and ARDS mortality.
AuthorsTadeo Bermudez, Saad Sammani, Jin H Song, Vivian Reyes Hernon, Carrie L Kempf, Alexander N Garcia, Jessica Burt, Matthew Hufford, Sara M Camp, Anne E Cress, Ankit A Desai, Viswanathan Natarajan, Jeffrey R Jacobson, Steven M Dudek, Leopoldo C Cancio, Julie Alvarez, Ruslan Rafikov, Yansong Li, Donna D Zhang, Nancy G Casanova, Christian Bime, Joe G N Garcia
JournalScientific reports (Sci Rep) Vol. 12 Issue 1 Pg. 696 (01 13 2022) ISSN: 2045-2322 [Electronic] England
PMID35027578 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright© 2022. The Author(s).
Chemical References
  • Antibodies, Neutralizing
  • Biomarkers
  • Lipopolysaccharides
  • NF-kappa B
  • Nicotinamide Phosphoribosyltransferase
  • Mechanistic Target of Rapamycin Complex 2
  • Proto-Oncogene Proteins c-akt
Topics
  • Acute Chest Syndrome (metabolism)
  • Animals
  • Antibodies, Neutralizing (metabolism)
  • Biomarkers (metabolism)
  • COVID-19 (metabolism)
  • Disease Models, Animal
  • Inflammation (metabolism)
  • Lipopolysaccharides (metabolism)
  • Lung (metabolism)
  • Male
  • Mechanistic Target of Rapamycin Complex 2 (metabolism)
  • NF-kappa B (metabolism)
  • Nicotinamide Phosphoribosyltransferase (metabolism)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • SARS-CoV-2 (pathogenicity)
  • Signal Transduction (physiology)
  • Swine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: